CN105535466A - 一种治疗青春期多囊卵巢综合征的药物组合物 - Google Patents
一种治疗青春期多囊卵巢综合征的药物组合物 Download PDFInfo
- Publication number
- CN105535466A CN105535466A CN201610045857.4A CN201610045857A CN105535466A CN 105535466 A CN105535466 A CN 105535466A CN 201610045857 A CN201610045857 A CN 201610045857A CN 105535466 A CN105535466 A CN 105535466A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- adolescence
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 30
- 206010036049 Polycystic ovaries Diseases 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 66
- 210000003734 kidney Anatomy 0.000 claims abstract description 42
- 239000008280 blood Substances 0.000 claims abstract description 41
- 210000004369 blood Anatomy 0.000 claims abstract description 39
- 238000011282 treatment Methods 0.000 claims abstract description 38
- 241000628997 Flos Species 0.000 claims abstract description 28
- 230000007812 deficiency Effects 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- 244000088424 Cyperus michelianus Species 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000006837 decompression Effects 0.000 claims description 10
- 238000002481 ethanol extraction Methods 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000004064 recycling Methods 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- -1 sublimed preparation Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 244000150195 Cyperus longus Species 0.000 abstract 1
- 235000018109 Cyperus longus Nutrition 0.000 abstract 1
- 240000002024 Gossypium herbaceum Species 0.000 abstract 1
- 235000004341 Gossypium herbaceum Nutrition 0.000 abstract 1
- 241000208682 Liquidambar Species 0.000 abstract 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 abstract 1
- 235000004879 dioscorea Nutrition 0.000 abstract 1
- 238000010926 purge Methods 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 13
- 210000001672 ovary Anatomy 0.000 description 13
- 239000003390 Chinese drug Substances 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 12
- 235000019634 flavors Nutrition 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 235000009508 confectionery Nutrition 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 201000000736 Amenorrhea Diseases 0.000 description 9
- 206010001928 Amenorrhoea Diseases 0.000 description 9
- 231100000540 amenorrhea Toxicity 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000005906 menstruation Effects 0.000 description 9
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 230000004087 circulation Effects 0.000 description 7
- 208000019255 Menstrual disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 208000037093 Menstruation Disturbances Diseases 0.000 description 5
- 230000002146 bilateral effect Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000016087 ovulation Effects 0.000 description 5
- 210000004681 ovum Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010020112 Hirsutism Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 208000021267 infertility disease Diseases 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 230000027758 ovulation cycle Effects 0.000 description 4
- 238000004080 punching Methods 0.000 description 4
- 230000003014 reinforcing effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010002659 Anovulatory cycle Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010021033 Hypomenorrhoea Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 206010047998 Withdrawal bleed Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 201000010066 hyperandrogenism Diseases 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 201000005670 Anovulation Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 231100000552 anovulation Toxicity 0.000 description 2
- 230000002513 anti-ovulatory effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域,涉及一种治疗青春期多囊卵巢综合征的药物组合物。该药物组合物由熟地黄、巴戟天、淫羊藿、当归、护心草、山茱萸、山药、黄精、路路通、沉香、棉花根、玫瑰花为原料药精心制成,诸药配伍阴阳并调,气血并补,同时活血祛瘀,寓补于疏,补而不滞;寓通于补,通而不泻。经临床应用验证,其对青春期多囊卵巢综合征尤其是肾虚血瘀型多囊卵巢综合征有极强的针对性疗效,且药性平和,未出现毒副作用及明显不良反应,安全系数高。
Description
技术领域
本发明属于医药技术领域,涉及一种治疗青春期多囊卵巢综合征的药物组合物。
背景技术
多囊卵巢综合征(polycysticovariansyndrome,PCOS)是一种发病多因性、临床表现呈多态性的内分泌综合征,以慢性无排卵、高雄激素血症和卵巢多囊性改变为临床主要特征,是妇产科临床上较为常见的内分泌紊乱性疾病,在中国乃至世界都是导致生育期妇女月经紊乱最常见的原因之一。PCOS长期以来被公认是一个异质性综合征,主要表现为无排卵型月经异常、不孕、多毛、痊疮、肥胖和卵巢多囊性变。
目前青春期PCOS患者多推荐给予达英-35等药物治疗,但患者因年纪较轻,尚未生育,多数不能接受服用激素类药物治疗,且部分患者接受治疗后一旦停药又易反复。中药治疗本病不失为一种安全、有效的方法,且患者易于接受。
本病属中医学“闭经”、“月经稀少”或“月经后期”、“不孕”、“癥瘕”等范畴。中医学认为肾为先天之本,冲任之本在于肾,肾藏精,主生殖,肾精又参与经血的组成,与月经关系密切。现代医学认为PCOS核心病机是由于卵泡不能发育成熟和卵泡壁的过度增生不能破裂导致卵泡闭锁,以上病理改变属于中医肾虚范畴,为肾中阴阳的“质”和“量”失衡所致。卵泡闭锁、间质增生、卵巢增大,均为肾虚基础上伴有血瘀导致的改变。
发明内容
为了解决上述问题,本发明旨在提供一种具有组方严谨,配伍科学,疗效显著,能最大限度地发挥药物疗效,并且制备方便,患者依从性好,无毒副作用的治疗青春期多囊卵巢综合征的药物组合物及其制备方法。
本发明的一个目的是提供一种治疗青春期多囊卵巢综合征的药物组合物。
本发明的另一个目的是提供一种治疗青春期多囊卵巢综合征的药物组合物的制备方法。
发明人结合古今先贤的理论与自己的临床经验,把西医辨病、辨因的微观检测与中医宏观辨证施治相结合,提供的一种治疗青春期多囊卵巢综合征的药物组合物,由熟地黄、巴戟天、淫羊藿、当归、护心草、山茱萸、山药、黄精、路路通、沉香、棉花根、玫瑰花为原料药精心制成。
本发明优选技术方案是本发明所述的药物组合物由以下重量份的原料药制成:熟地黄13-18份、巴戟天6-11份、淫羊藿5-9份、当归10-15份、护心草12-17份、山茱萸3-7份、山药20-30份、黄精5-9份、路路通4-7份、沉香2-4份、棉花根10-15份、玫瑰花8-12份。
本发明进一步优选技术方案是本发明所述的药物组合物由以下重量份的原料药制成:熟地黄15份、巴戟天10份、淫羊藿6份、当归12份、护心草15份、山茱萸4份、山药20份、黄精8份、路路通6份、沉香3.5份、棉花根15份、玫瑰花10份。
发明人总结认为:中医认为卵子是生殖之精,卵子的发育成熟与肾精充盛密切相关,卵子的正常排出又有赖于肾阳的鼓动以使冲任气血调畅。肾精亏虚使卵子缺乏物质基础,难以发育成熟;肾阳亏虚既不能鼓舞肾阴的生化和滋长,又使气血运行无力而瘀滞冲任胞脉,更使排卵缺乏原动力,故肾虚是排卵障碍的根本原因。肾虚又进一步导致阴阳气血失常,水湿内停,痰湿内生,壅阻冲任胞脉,气血瘀滞成癥,使卵子难以排出、卵巢增大,故肾虚血瘀是PCOS的基本病机。方中:熟地黄甘,微温,善滋阴补血,益精填髓;巴戟天辛,甘,温,善入肾经血分,能补助元阳,而兼散邪,强筋壮骨,淫羊藿善入肾经气分,辛能散结,甘能缓中,温能通气行血,能益精气,真阳不足;三药配伍为君药,滋肾补水,温补肾阳,于“阳中求阴”、“阴中求阳”。
护心草行气养血,调经;当归补血活血,调经止痛;二药配伍使用能行气养血,助君药生精化气,君臣配伍,气血并补阴阳相生,刚柔相济,使肾之元气生化无穷。
山茱萸酸、涩,微温,气温而主补,味酸而主敛,补益肝肾,涩精固脱,山药甘,平,能健脾补虚,滋精固肾,治诸虚百损,疗五劳七伤;黄精甘,平,补气养阴,健脾,润肺,益肾,平补气血而润;三药配伍,补肝肾强筋骨、润五脏,调节身体机能。沉香能温养脏腑,保和卫气佐臣药能和血,能散瘀,能定痛,能疏通经络;棉花根止咳平喘,通经止痛;玫瑰花理气解郁,和血散瘀,具为佐使药。
路路通苦,平,祛风除湿,疏肝活络,利水,为使药。
诸药配伍滋肾补水,温补肾阳,阴阳并调,气血并补,刚柔相济,同时活血祛瘀,寓补于疏,补而不滞;寓通于补,通而不泻。对青春期多囊卵巢综合征尤其是肾虚血瘀型多囊卵巢综合征有极强的针对性疗效。
本发明所用各药材的药理学研究现状如下所述。
熟地黄:【性味】甘,微温。【归经】归肝、肾经。【功能主治】滋阴补血,益精填髓。用于肝肾阴虚,腰膝酸软,骨蒸潮热,盗汗遗精,内热消渴,血虚萎黄,心悸怔忡,月经不调,崩漏下血,眩晕,耳鸣,须发早白。
巴戟天:【性味】辛甘;温。【归经】肝;肾经。【功能主治】补肾助阳;强筋壮骨;祛风除湿。主肾虚阳痿;遗精早泄;少腹冷痛;小便不禁;宫冷不孕;风寒湿痹;腰膝酸软;风湿肢气。
淫羊藿:【性味】辛、甘,温。【归经】归肝、肾经。【功能主治】补肾阳,强筋骨,祛风湿。用于阳痿遗精,筋骨痿软,风湿痹痛,麻木拘挛;更年期高血压。《纲目》:"淫羊藿,性温不寒,能益精气,真阳不足者宜之。
护心草:【性味】味辛;淡;性平。【归经】肝;脾经。【功能主治】行气养血;调经。主月经不调;痛经。【用法用量】内服:煎汤,9-15g;或研末。
当归:【性味】味甘、辛、苦,性温,【归经】入肝、心、脾经,【功能主治】补血活血,调经止痛、润汤通便的作用,用于血虚萎黄、眩晕心悸、月经不调、经闭痛经、虚寒腹痛、肠燥便秘、风湿痹痛、跌扑损伤、痈疽疮疡等证。《注解伤寒论》:“脉者血之府,诸血皆属心,凡通脉者必先补心益血,故张仲景治手足厥寒,脉细欲绝者,用当归之苦温以助心血。”
山茱萸:【性味】酸、涩,微温。【归经】归肝、肾经。【功能主治】补益肝肾,涩精固脱。用于眩晕耳鸣,腰膝酸痛,阳痿遗精,遗尿尿频,崩漏带下,大汗虚脱。内热消渴。【用法用量】6~12g。现代研究表明,山茱萸有降血糖的作用。
山药:【性味】甘,平。【归经】归脾、肺、肾经。【功能主治】补脾养胃,生津益肺,补肾涩精。用于脾虚食少,久泻不止,肺虚喘咳,肾虚遗精,带下,尿频,虚热消渴。麸炒山药补脾健胃。用于脾虚食少,泄泻便溏,白带过多。现代研究表明,山药提取物对四氧嘧啶糖尿病小鼠有降血糖的作用。
黄精:【性味】甘,平。【归经】归脾、肺、肾经。【功能主治】补气养阴,健脾,润肺,益肾。用于脾胃虚弱,体倦乏力,口干食少,肺虚燥咳,精血不足,内热消渴。【用法用量】9~15g。
沉香:【性味】辛、苦,微温。【归经】归脾、胃、肾经。【功能主治】行气止痛,温中止呕,纳气平喘。用于胸腹胀闷疼痛,胃寒呕吐呃逆,肾虚气逆喘急。
棉花根:【性味】味甘;性温。【归经】肺;脾;肝经。【功能主治】止咳平喘;通经止痛。主咳嗽;气喘;有经不调;崩漏。
玫瑰花:【性味】甘、微苦,温。【归经】归肝、脾经。【功能主治】行气解郁,和血,止痛。用于肝胃气痛,食少呕恶,月经不调,跌扑伤痛。
路路通:【性味】苦;平。【归经】十二经。【功能主治】祛风除湿;疏肝活络;利水。主风湿痹痛;肢体麻木;手足拘挛;脘腹疼痛;经闭;乳汁不通;水肿胀满;湿疹。【用法用量】内服:煎汤;3-10g;或煅存性研末服。外用:适量,研末敷;或烧烟闻嗅。
为了更好地表达本发明的药物组合物,本发明的药物组合物可由熟地黄、巴戟天、淫羊藿、当归、护心草、山茱萸、山药、黄精、路路通、沉香、棉花根、玫瑰花或其水或其有机溶剂提取物为活性成分,加入药学上可接受的辅料或辅助性成分制备成药学上常用的剂型。
所述的药学上可接受的载体或辅助性成分,如淀粉、糖粉、糊精、微晶纤维、可压性淀粉、微粉硅胶、果糖、羧甲基淀粉钠、羧甲基纤维素钠、羟丙基甲基纤维素、植物油、卵磷脂、聚乙二醇、丙二醇、尼泊金乙酯、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙,等等。
本发明所述的药物组合物优选制成为口服剂型,比如:片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、颗粒剂、蜜丸剂、散剂、丹剂、溶液剂等。
优选地,上述所述的药物组合物优选制成片剂、胶囊剂或颗粒剂,最优选为胶囊剂。
本发明还提供了该药物组合物的制备方法,它包括如下步骤:
(1)玫瑰花、巴戟天、淫羊藿加入3-8倍量80%乙醇,回流提取两次,每次1-3小时,滤过,合并两次滤液,减压回收乙醇至无醇味,继续减压浓缩成干浸膏,冷冻干燥,粉碎得乙醇提取物;
(2)将玫瑰花、巴戟天、淫羊藿乙醇提取后滤渣与熟地黄、当归、护心草、山茱萸、山药、黄精、路路通、棉花根合并,加5-10倍量水,煎煮提取3次,每次1-3小时,合并滤液,滤过,浓缩至相对密度1.05-1.10(60℃测),放置至室温,加入乙醇使含醇量达30%,搅匀,-5-0℃冷藏12小时,滤过,滤液减压回收乙醇至无醇味,冷冻干燥,粉碎得水提取物;
(3)将沉香粉碎成200目以上的细粉,与步骤(1)-(2)的提取物混合均匀,得到药物活性成分;该成分单独或与药物可接受的载体混合,依照制剂学常规技术制成。
本发明还请求保护上述药物组合物在制备治疗青春期多囊卵巢综合征的药物中的用途。在临床观察过程中,中药组72例PCOS患者,显效41例,有效29例,无效2例,显效率56.9%,总有效率97.2%,与西药组显效率、总有效率比较,差异有统计学意义(P<0.05),在治疗3个周期后,血中LH/FSH、T下降,与治疗前比较差异有显著性(P<0.01)。但在停药后3个周期,中药组疗效较西药组肯定,差异有显著性(P<0.01),且月经恢复正常、排卵恢复明显高于西药组。说明本发明药物在治疗青春期PCOS中不但能收到近期明显效果,而且可巩固疗效,易于为青春期患者及家属所接受,为一种治疗PCOS的有效方法。详述如下。
1资料与方法
1.1病例选择
1.1.1西医诊断标准:参照欧洲人类生殖协会和美国生殖协会于2003年在鹿特丹联合发起的PCOS研讨会制定的标准:(1)偶发排卵和(或)无排卵的症状,月经异常(稀发、量少、闭经、功血);(2)存在高雄激素血症的表现:临床(包括痤疮、多毛、秃顶)和(或)生化指标(排除先天性肾上腺增生,分泌雄激素肿瘤和Cushing综合征等可能致病的因素;(3)B超提示双侧卵巢多囊性改变:双侧卵巢体积增大,各有≥10个直径在2~8mm的小卵泡。(无月经来潮者,在B超提示双侧卵巢均无优势卵泡时检测)。以上具备任意两个或以上者,并且近3个月未使用过甾体激素类药物者。
1.1.2中医辨证标准:对于符合上述西医诊断标准者,参照1994年国家中医药管理局颁布的《中医病证诊断疗效标准》及《中药新药临床研究指导原则》属于肾虚血瘀型。证见:月经稀发或闭经,或周期紊乱,或婚久不孕,腰腿酸软,头晕耳鸣,性欲冷淡,少腹疼痛,舌黯淡或有瘀斑,脉沉涩。上述主证具备3项或以上,辨证为肾虚血瘀型。
1.1.3病例纳入标准:符合上述诊断标准者;年龄≥15岁,且<20岁,自愿参加治疗并可定期复诊者。
1.1.4病例排除标准:辨证不符合肾虚血瘀证者;具有其他内分泌疾病,如先天性肾上腺皮质增生、柯兴综合征、卵巢或肾上腺肿瘤、高催乳激素血症、糖尿病等者;近3个月用过激素类药物者;过敏体质或对本药过敏者;符合纳入标准,但未按规定服药,无法判断疗效或资料不全无法进行疗效评价者。
1.2一般资料:选择2014年1月至2014年12月我院妇科门诊确诊为PCOS患者108例,年龄在15~19岁之间,按随机数字表法,随机分为两组。西药组36例,平均年龄(15.8±2.6)岁;病程6个月~3年,平均(1.05±0.52)年,继发性闭经8例,月经稀发6例;多毛6例,肥胖2例,面部痤疮3例。中药组72例,平均年龄(16.2±2.8)岁;病程6个月~3年,平均(1.12±0.60)年;原发性闭经1例,继发性闭经15例,月经稀发13例;多毛11例,肥胖3例,面部痤疮5例。两组一般资料比较无统计学差异(P>0.05),具有可比性。
1.3治疗方法
西药组:于自然月经或撤退性出血第5天开始口服达英-35(每片含醋酸环丙孕酮2mg和炔雌醇35μg,德国先灵公司生产),每日1片,连服21d,停药后待撤退性出血第5天起重复服用,共3个周期。
中药组:口服本发明实施例1制备的胶囊,每日2次,每次2-4粒,饭后半小时服用,一个月经周期为一疗程,逢经期停用,共治疗3个疗程。
1.4观察指标:
1.4.1观察治疗前、治疗3个周期后及停药后第3个周期患者的月经改善情况(主要询问患者月经来潮时间,月经量、色、质情况),排卵情况(自测基础体温),以及B超测量子宫、卵巢各径线大小,排卵时子宫内膜厚度;
1.4.2于月经来潮或撤退性出血3~5d,清晨空腹静脉抽血,分别测定血清性激素(卵泡刺激素(FSH)、黄体生成素(LH)、睾酮(T))水平;
1.4.3治疗前后检测肝功能水平,以观察两组的毒副反应情况。
1.5疗效标准:参照《中药新药临床研究指导原则》标准拟订。显效:月经周期恢复正常,停药后月经规则连续>3个周期,临床症状明显减轻,基础体温双相,生理激素水平基本正常,B超提示卵巢恢复正常大小;有效:月经周期基本恢复正常,停药后3个周期病情偶有复发,临床症状有所减轻,生理激素水平趋于正常,B超提示卵巢较治疗前有所缩小;无效:月经紊乱,甚或仍然闭经,临床症状及生理激素水平无明显改善,B超检查无明显改善。总有效率=(显效例数+有效例数)/总例数×100%。
1.6统计学方法:采用SPSS15.0统计软件进行计算。各数值以表示,计量资料采用t检验,计数资料采用χ2检验,以P<0.05为差异有统计学意义。
2结果
2.1两组患者多囊卵巢综合征疗效比较:治疗后中药组显效41例,有效29例,无效2例,显效率56.9%,总有效率97.2%;西药组显效11例,有效16例,无效9例,显效率30.6%,总有效率75.0%,中药组与西药组显效率、总有效率比较,差异有统计学意义(P<0.05),说明中药组较西药组可以明显的提高青春期多囊卵巢综合征患者的临床治愈率及显效率。
见表1。
表1两组患者疗效比较(n%,例)
注:与西药组比较,*P<0.05。
2.2两组血清内分泌激素指标比较:治疗前两组患者血清内分泌激素各项指标比较,无显著性差异(P>0.05)。中药组治疗前后LH/FSH、T值比较均有极其显著性差异(P<0.01),西药组治疗前后LH/FSH、T值比较有显著性差异(P<0.01);停药后第3周期,西药组激素水平又恢复到治疗前水平,中药组仍保持治疗后的水平(P<0.01),且较西药组同期下降明显(P<0.01)。见表2。
表2两组血清内分泌激素指标比较
注:与治疗前比较,*P<0.05,**P<0.01,与西药组同期比较,#P<0.05。
2.3两组治疗前后B超检查指标变化两组治疗前B超检查指标比较差异无显著性,治疗3个周期后患者的子宫体积均无明显变化(P>0.05),子宫内膜厚度、双侧卵巢体积均明显减小(P<0.01)。停药后第3个周期,西药组患者B超检查的各项指标又基本恢复到治疗前的状况,中药组仍保持在治疗后的状况(P<0.01),且子宫内膜厚度、双侧卵巢体积较西药组同期均明显减小(P<0.01)。
2.4副反应西药组治疗的患者中9例患者出现恶心,胃胀等胃肠道反应,经对症治疗后好转;5例出现乳房胀痛,月经前较明显;中药组未诉不适。西药组丙氨酸氨基转移酶升高,4例升高至40~80IU/L,中药组肝肾功能无明显受损,两组比较,差异有统计学意义(P<0.01)。
总之:本发明相对与现有技术,有如下明显优势:首先,本发明药物组合物组方主要是依据肾虚血瘀型青春期多囊卵巢综合征的病机特点研制而成,有极强的针对性疗效。
本发明组方精简,配伍合理,成本低廉,经临床应用验证,其疗效确切,药性平和,未出现毒副作用及明显不良反应,安全系数高。
本发明中药制剂采用先进提取设备和工艺,充分提取有效成分,可制成方便口服或携带的中药制剂,如片剂、胶囊剂或颗粒剂。
具体实施方式
以下通过具体实施例进一步描述本发明,本发明不仅仅限于以下实施例。在本发明的范围内或者在不脱离本发明的内容、精神和范围内,对本发明进行的变更、组合或替换,对于本领域的技术人员来说是显而易见的,且包含在本发明的范围之内。
实施例1胶囊剂
处方:熟地黄15份、巴戟天10份、淫羊藿6份、当归12份、护心草15份、山茱萸4份、山药20份、黄精8份、路路通6份、沉香3.5份、棉花根15份、玫瑰花10份。
制备方法:
(1)玫瑰花、巴戟天、淫羊藿加入3-8倍量80%乙醇,回流提取两次,每次1-3小时,滤过,合并两次滤液,减压回收乙醇至无醇味,继续减压浓缩成干浸膏,冷冻干燥,粉碎得乙醇提取物;
(2)将玫瑰花、巴戟天、淫羊藿乙醇提取后滤渣与熟地黄、当归、护心草、山茱萸、山药、黄精、路路通、棉花根合并,加5-10倍量水,煎煮提取3次,每次1-3小时,合并滤液,滤过,浓缩至相对密度1.05-1.10(60℃测),放置至室温,加入乙醇使含醇量达30%,搅匀,-5-0℃冷藏12小时,滤过,滤液减压回收乙醇至无醇味,冷冻干燥,粉碎得水提取物;
(3)将沉香粉碎成200目以上的细粉,与步骤(1)-(2)的提取物混合均匀,得到药物活性成分,依照制剂学常规技术制成。
本实施例胶囊剂每粒含有生药0.6g。
实施例2胶囊剂
处方:熟地黄13份、巴戟天8份、淫羊藿8份、当归10份、护心草15份、山茱萸6份、山药25份、黄精5份、路路通5份、沉香3.0份、棉花根12份、玫瑰花10份。
制备方法:参照实施例1。
实施例3胶囊剂
处方:熟地黄15份、巴戟天7份、淫羊藿9份、当归15份、护心草12份、山茱萸6份、山药30份、黄精6份、路路通4份、沉香4份、棉花根10份、玫瑰花12份。
制备方法:参照实施例1。
实施例4胶囊剂
处方:熟地黄18份、巴戟天10份、淫羊藿8份、当归15份、护心草15份、山茱萸5份、山药26份、黄精7份、路路通5份、沉香3.5份、棉花根15份、玫瑰花12份。
制备方法:参照实施例1。
实施例5片剂
处方:熟地黄13份、巴戟天8份、淫羊藿8份、当归15份、护心草17份、山茱萸4份、山药25份、黄精7份、路路通6份、沉香3.5份、棉花根15份、玫瑰花8份。
制备方法:(1)玫瑰花、巴戟天、淫羊藿加入3-8倍量80%乙醇,回流提取两次,每次1-3小时,滤过,合并两次滤液,减压回收乙醇至无醇味,继续减压浓缩成干浸膏,冷冻干燥,粉碎得乙醇提取物;
(2)将玫瑰花、巴戟天、淫羊藿乙醇提取后滤渣与熟地黄、当归、护心草、山茱萸、山药、黄精、路路通、棉花根合并,加5-10倍量水,煎煮提取3次,每次1-3小时,合并滤液,滤过,浓缩至相对密度1.05-1.10(60℃测),放置至室温,加入乙醇使含醇量达30%,搅匀,-5-0℃冷藏12小时,滤过,滤液减压回收乙醇至无醇味,冷冻干燥,粉碎得水提取物;
(3)将沉香粉碎成200目以上的细粉,与步骤(1)-(2)的提取物混合均匀,得到药物活性成分,依照制剂学常规技术制成。
本实施例片剂每片含有生药0.6g。
实施例6片剂
处方:熟地黄15份、巴戟天11份、淫羊藿8份、当归10份、护心草16份、山茱萸5份、山药28份、黄精7份、路路通7份、沉香3.5份、棉花根15份、玫瑰花10份。
制备方法:参照实施例5。
实施例7颗粒剂
处方:熟地黄15份、巴戟天10份、淫羊藿6份、当归12份、护心草15份、山茱萸4份、山药20份、黄精8份、路路通6份、沉香3.5份、棉花根15份、玫瑰花10份。
制备方法:(1)玫瑰花、巴戟天、淫羊藿加入3-8倍量80%乙醇,回流提取两次,每次1-3小时,滤过,合并两次滤液,减压回收乙醇至无醇味,继续减压浓缩成干浸膏,冷冻干燥,粉碎得乙醇提取物;
(2)将玫瑰花、巴戟天、淫羊藿乙醇提取后滤渣与熟地黄、当归、护心草、山茱萸、山药、黄精、路路通、棉花根合并,加5-10倍量水,煎煮提取3次,每次1-3小时,合并滤液,滤过,浓缩至相对密度1.05-1.10(60℃测),放置至室温,加入乙醇使含醇量达30%,搅匀,-5-0℃冷藏12小时,滤过,滤液减压回收乙醇至无醇味,冷冻干燥,粉碎得水提取物;
(3)将沉香粉碎成200目以上的细粉,与步骤(1)-(2)的提取物混合均匀,得到药物活性成分,依照制剂学常规技术制成。
本实施例颗粒剂每袋含有生药2.0g。
实施例8颗粒剂
处方:熟地黄16份、巴戟天8份、淫羊藿8份、当归10份、护心草15份、山茱萸4份、山药20份、黄精8份、路路通6份、沉香2份、棉花根15份、玫瑰花10份。
制备方法:参照实施例7。
Claims (10)
1.一种治疗青春期多囊卵巢综合征的药物组合物,其特征在于由熟地黄、巴戟天、淫羊藿、当归、护心草、山茱萸、山药、黄精、路路通、沉香、棉花根、玫瑰花为原料药制成。
2.如权利要求1所述的治疗青春期多囊卵巢综合征的药物组合物,其特征在于由以下优选重量份的原料药制成:熟地黄13-18份、巴戟天6-11份、淫羊藿5-9份、当归10-15份、护心草12-17份、山茱萸3-7份、山药20-30份、黄精5-9份、路路通4-7份、沉香2-4份、棉花根10-15份、玫瑰花8-12份。
3.如权利要求2所述的治疗青春期多囊卵巢综合征的药物组合物,其特征在于由以下优选重量份的原料药制成:熟地黄15份、巴戟天10份、淫羊藿6份、当归12份、护心草15份、山茱萸4份、山药20份、黄精8份、路路通6份、沉香3.5份、棉花根15份、玫瑰花10份。
4.如权利要求1-3所述的治疗青春期多囊卵巢综合征的药物组合物,其特征在于所述药物组合物优选制成为口服剂型。
5.如权利要求4所述的治疗青春期多囊卵巢综合征的药物组合物,其特征在于所述口服剂型为片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、颗粒剂、蜜丸剂、散剂、丹剂、溶液剂等。
6.如权利要求5所述的治疗青春期多囊卵巢综合征的药物组合物,其特征在于所述口服剂型为片剂、胶囊剂或颗粒剂。
7.如权利要求6所述的治疗青春期多囊卵巢综合征的药物组合物,其特征在于所述口服剂型为颗粒剂。
8.如权利要求1-3所述的治疗青春期多囊卵巢综合征的药物组合物,其特征在于制备方法括如下步骤:
(1)玫瑰花、巴戟天、淫羊藿加入3-8倍量80%乙醇,回流提取两次,每次1-3小时,滤过,合并两次滤液,减压回收乙醇至无醇味,继续减压浓缩成干浸膏,冷冻干燥,粉碎得乙醇提取物;
(2)将玫瑰花、巴戟天、淫羊藿乙醇提取后滤渣与熟地黄、当归、护心草、山茱萸、山药、黄精、路路通、棉花根合并,加5-10倍量水,煎煮提取3次,每次1-3小时,合并滤液,滤过,浓缩至相对密度1.05-1.10(60℃测),放置至室温,加入乙醇使含醇量达30%,搅匀,-5-0℃冷藏12小时,滤过,滤液减压回收乙醇至无醇味,冷冻干燥,粉碎得水提取物;
(3)将沉香粉碎成200目以上的细粉,与步骤(1)-(2)的提取物混合均匀,得到药物活性成分;该成分单独或与药物可接受的载体混合,依照制剂学常规技术制成。
9.如权利要求1-3所述的药物组合物在制备治疗青春期多囊卵巢综合征的药物中的用途。
10.如权利要求1-3所述的药物组合物在制备治疗青春期肾虚血瘀型多囊卵巢综合征的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610045857.4A CN105535466A (zh) | 2016-01-25 | 2016-01-25 | 一种治疗青春期多囊卵巢综合征的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610045857.4A CN105535466A (zh) | 2016-01-25 | 2016-01-25 | 一种治疗青春期多囊卵巢综合征的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105535466A true CN105535466A (zh) | 2016-05-04 |
Family
ID=55815374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610045857.4A Withdrawn CN105535466A (zh) | 2016-01-25 | 2016-01-25 | 一种治疗青春期多囊卵巢综合征的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105535466A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106110163A (zh) * | 2016-08-08 | 2016-11-16 | 林夏欢 | 健胃养生茶冲剂的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102319405A (zh) * | 2011-09-30 | 2012-01-18 | 张鸿翔 | 一种治疗多囊卵巢综合症的中药组合物 |
CN102895456A (zh) * | 2011-07-25 | 2013-01-30 | 刘艳萍 | 治疗多囊卵巢综合征的药物 |
CN103272144A (zh) * | 2013-05-24 | 2013-09-04 | 孙炳云 | 一种治疗多囊卵巢综合症的药物 |
CN104940740A (zh) * | 2015-07-01 | 2015-09-30 | 袁明圆 | 一种治疗多囊卵巢综合征的中药组合物及其制备方法 |
-
2016
- 2016-01-25 CN CN201610045857.4A patent/CN105535466A/zh not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102895456A (zh) * | 2011-07-25 | 2013-01-30 | 刘艳萍 | 治疗多囊卵巢综合征的药物 |
CN102319405A (zh) * | 2011-09-30 | 2012-01-18 | 张鸿翔 | 一种治疗多囊卵巢综合症的中药组合物 |
CN103272144A (zh) * | 2013-05-24 | 2013-09-04 | 孙炳云 | 一种治疗多囊卵巢综合症的药物 |
CN104940740A (zh) * | 2015-07-01 | 2015-09-30 | 袁明圆 | 一种治疗多囊卵巢综合征的中药组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
何清湖等: "《妇科良方大全》", 31 October 2006, 山西科学技术出版社 * |
齐玲玲等: "补肾化瘀为主治疗多囊卵巢综合征35例", 《山东中医杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106110163A (zh) * | 2016-08-08 | 2016-11-16 | 林夏欢 | 健胃养生茶冲剂的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN104922543A (zh) | 一种治疗闭经的药物组合物及其制备方法 | |
CN103041208A (zh) | 一种治疗妇女更年期综合征的中药制剂及其制备方法 | |
CN104958607A (zh) | 一种治疗妇女更年期灼口综合征的中药组合物及方法 | |
CN104940740A (zh) | 一种治疗多囊卵巢综合征的中药组合物及其制备方法 | |
CN105169212A (zh) | 一种用于治疗慢性胃炎的中药组合物 | |
CN103432559A (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
CN104645249B (zh) | 一种治疗冠心病心绞痛的药物 | |
CN105311470A (zh) | 含有艾叶的药物组合物用于制备治疗糖尿病肾病药物中的用途 | |
CN105944020B (zh) | 一种治疗卵巢功能下降的中药 | |
CN102048913B (zh) | 一种治疗更年期综合症的中药制剂及其制备方法 | |
CN104524479B (zh) | 一种治疗经前期综合征的中药组合物及其制备方法 | |
CN105535466A (zh) | 一种治疗青春期多囊卵巢综合征的药物组合物 | |
CN105497262A (zh) | 一种治疗肝肾阴虚型多囊卵巢综合征的药物组合物 | |
CN104623374A (zh) | 一种治疗急性放射病的中药制剂及其制备方法 | |
CN104189615B (zh) | 一种治疗崩漏的中药制剂及其制备方法 | |
CN105535199A (zh) | 一种治疗多囊卵巢综合征合并乳腺增生的药物制剂 | |
CN106177404A (zh) | 一种治疗肝肾阴虚的中药组合物及其制备方法 | |
CN105597020A (zh) | 一种治疗多囊卵巢综合征合并乳腺增生的药物组合物 | |
CN106309980B (zh) | 一种保胎药及其制备方法 | |
CN105250634A (zh) | 一种用于治疗产后便秘的中药组合物及其用途 | |
CN119326862A (zh) | 组合物及具有其的药物、联合药物和用途 | |
CN103301303A (zh) | 一种治疗糖尿病的中药组合物 | |
CN105833031A (zh) | 一种用于甲状腺癌术后心肾阴虚证的药物组合物 | |
CN105902934A (zh) | 一种用于甲状腺癌骨转移放疗的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160504 |